CD80 Targeted Therapies
2 drugsAbout CD80
CD80 is a protein on immune cells that acts as a costimulatory molecule, modulating immune responses. It interacts with other molecules on immune cells to enhance or suppress their activity, which is vital for T cell activation.
CD80 is a therapeutic target with moderate genetic support (max score 0.65). Loss-of-function variants are protective against vitiligo (score 0.65) and systemic lupus erythematosus (score 0.56), suggesting inhibition may be beneficial.
Two FDA-approved drugs, ORENCIA and NULOJIX, target CD80 as fusion proteins. Both drugs are marketed by Bristol-Myers Squibb for indications beyond common therapeutic areas.
CD80 Genetic Evidence Moderate
Genetic evidence provides moderate support for CD80 as a drug target.
A score of 0.65 suggests CD80 is a viable target, but further validation may be needed.
💡 Why inhibition?
- • Loss-of-function variants reduce disease risk (OR < 1)
- • 100% directional consistency across 2 traits
- • Strong signal in immune system disease, integumentary system disease pathways
Cross-Disease Effects
Trade-off: LowDirection of Effect
100% alignedEvidence Across Diseases
10 totalGWAS and other genetic studies link CD80 to 10 diseases.
Inhibiting this target may be therapeutic
Inhibiting this target may be therapeutic
🔗 Colocalization Evidence 20 strong
max H4: 1.00eQTL/pQTL signals for CD80 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top CD80 Drugs
Bristol-Myers Squibb is the only company with approved drugs targeting CD80.
The lack of competitors suggests high barriers to entry or untapped market potential.
CD80 Drug Modality Landscape
Modalities
Routes of Administration
CD80 requires biologic approaches (fusion protein), likely due to its structure or location.
Exploring alternative modalities like antibodies or small molecules could provide a competitive advantage.
CD80 Clinical Trials 170 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on CD80. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 39 | 25 | 5 | 9 | 83% |
| Phase 2 | 64 | 34 | 13 | 16 | 72% |
| Phase 3 | 33 | 25 | 1 | 7 | 96% |
| Phase 4 | 34 | 27 | 6 | 1 | 82% |
Top Sponsors
By Modality
Top Conditions
CD80 Drug Approval Timeline (2005 - 2011)
The first CD80-targeting drug was approved in 2005, and the most recent in 2011.
The limited approval span suggests a potentially saturated market or challenges in drug development.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 90 (8 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on CD80. A trial counts if an approved drug acting on CD80 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.